Service Line:+1-315-239-3085
Address:FL-4, Building A5, International Enterprise Community, Tianjin, China
Email:info@kmdbioscience.com
Catalog Number | YR1202 |
---|---|
Product Name | Anti-Human ITGAL & CD11a & CD18 Recombinant Antibody |
Molecular Name | Rovelizumab |
Alias | Anti-ITGAL & CD11a & CD18 Recombinant Antibody, Research Grade Rovelizumab |
CAS Number | 339086-79-2 |
Target | ITGAL & CD11a & CD18[Homo sapiens] |
Isotype | IgG4 |
Clonity | Monoclonal |
Source | CHO Cells |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Purity | >95% as determined by SDS-PAGE |
Buffer | PBS, pH7.5 |
Background | Rovelizumab, also known as LeukArrest and Hu23F2G, is a humanized monoclonal antibody which was an experimental immunosuppressive drug. Rovelizumab was developed by Icos to treat patients suffering from haemorrhagic shock. The drug is a monoclonal antibody that suppresses white blood cells which become overly active during shock. |
Storage | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
Note | This product is for research use only. |